The Australian Stroke Guidelines and the New Zealand Stroke Network recognized TNK, specifically at a dosage of 0.25 mg/kg (maximum 25 mg), as an alternative for ALT in 2019 [21]. The gene discussed is GPT; the disease is stroke disorder.